Related Experiment Video
Updated: Mar 28, 2026
Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
Published on: June 29, 2022
Conduction System Pacing Versus Right Ventricular Pacing in Atrioventricular Block: A Systematic Review and
Shaikh Muhammad Daniyal1, Komail Khalid Meer1, Minahil Javaid2
1Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Introduction:
Right ventricular pacing (RVP) is the standard therapy for atrioventricular (AV) block but may cause ventricular dyssynchrony with long-term use. This meta-analysis evaluates the efficacy and safety of conduction system pacing (CSP), including His bundle pacing (HBP) and left bundle branch area pacing (LBBAP), as a physiologic alternative to RVP.
Methods:
A systematic search was conducted across PubMed, Google Scholar, Cochrane CENTRAL, and ClinicalTrials.gov from inception to August 2025, for randomized controlled trials (RCTs). Outcomes were analyzed as risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs) and pooled using the Mantel-Haenszel random-effects model in R (version 4.4.2).
Results:
Five RCTs enrolling 659 patients were included. CSP was associated with a significant improvement in LVEF compared with RVP (MD: 1.31%; 95% CI: 0.49 to 2.14; p < 0.01). While CSP resulted in a significantly narrower paced QRS duration (MD: -28.44 ms; 95% CI: -38.96 to -17.92; p < 0.01), the procedure time was longer with CSP (MD: 25.86 min; 95% CI: 23.09 to 28.63; p < 0.01). The risk of device and lead-related complications was comparable between cohorts (RR: 1.35; 95% CI, 0.28 to 6.63; p = 0.71).
Conclusion:
Conduction system pacing (CSP) slightly improves LVEF and achieves a significantly narrower paced QRS compared with right ventricular pacing (RVP). Although associated with longer procedure times, CSP does not increase device- or lead-related complications. These findings suggest that CSP offers more physiological ventricular activation while maintaining comparable safety to conventional RVP.
Trial Registration:
PROSPERO number: CRD420251152303.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10:17Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
Related Concept Videos
01:18Dysrhythmias IV: Characteristics of Bradyarrhythmias
01:19Conduction System of the Heart
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
01:20Conduction System of the Heart
This system relies on the unique properties of nodal and Purkinje cells:...
01:29Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
01:13The Cardiac Cycle
The Process
Electrical signals—sent from the sinoatrial (SA) node in the right atrial wall to the atrioventricular (AV) node between the right atrium and right ventricle—cause both atria to simultaneously contract. When the signal reaches the AV node, it pauses for approximately a tenth of a second, allowing the atria to contract and...
01:25Dysrhythmias VI: Management of Dysrhythmias